Literature DB >> 27624902

[New aspects in the treatment of thyroid cancer : Highlights of the ASCO Annual Meeting 2016].

B B Lörincz1, C Simon2, N Möckelmann3, R Knecht3.   

Abstract

The annual meeting of the American Society of Clinical Oncology (ASCO) took place at the beginning of June 2016 in Chicago. This year a total of 28 studies on the treatment of patients with thyroid cancer were presented, described in this review article according to the degree of cancer cell differentiation. The leading curative treatment modality is still surgery. In contrast, kinase inhibitors are being used increasingly within palliative concepts. The latest state of the art of thyroid cancer treatment, both surgical and medical, is summarized in this review.

Entities:  

Keywords:  Kinase inhibitors; Metastasis; Palliative care; Surgery; Thyroid

Mesh：

Substances：

Year:  2016        PMID： 27624902     DOI： 10.1007/s00106-016-0246-3

Source DB:  PubMed          Journal:  HNO        ISSN： 0017-6192            Impact factor:   1.284


  3 in total

1.  Strong immunoexpression of midkine is associated with multiple lymph node metastases in BRAFV600E papillary thyroid carcinoma.

Authors:  Yong Won Choi; Young Hwa Kim; Jeonghun Lee; Euy Young Soh; Tae Jun Park; Jang-Hee Kim
Journal:  Hum Pathol       Date:  2015-07-02       Impact factor: 3.466

2.  Total thyroidectomy versus thyroid lobectomy for papillary thyroid cancer: Comparative analysis after propensity score matching: A multicenter study.

Authors:  Sayaka Kuba; Kosho Yamanouchi; Naomi Hayashida; Shigeto Maeda; Toshiyuki Adachi; Chika Sakimura; Fusako Kawakami; Hiroshi Yano; Megumi Matsumoto; Ryota Otsubo; Shuntaro Sato; Hikaru Fujioka; Tamotsu Kuroki; Takeshi Nagayasu; Susumu Eguchi
Journal:  Int J Surg       Date:  2016-09-24       Impact factor: 6.071

3.  Expression of miRNA and Occurrence of Distant Metastases in Patients with Hürthle Cell Carcinoma.

Authors:  Rok Petric; Barbara Gazic; Katja Goricar; Vita Dolzan; Radan Dzodic; Nikola Besic
Journal:  Int J Endocrinol       Date:  2016-07-28       Impact factor: 3.257
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.